Previous Close | 8.13 |
Open | 8.12 |
Bid | 7.55 x 200 |
Ask | 8.31 x 7000 |
Day's Range | 8.01 - 8.21 |
52 Week Range | 7.80 - 18.00 |
Volume | 308,815 |
Avg. Volume | 627,158 |
Market Cap | 851.072M |
Beta | 0.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.23 |
Earnings Date | Apr 30, 2018 - May 4, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.20 |
There's good reason to consider buying shares in these biotech companies soon.
THE WOODLANDS, Texas, April 03, 2018-- Lexicon Pharmaceuticals, Inc., announced today that it will host its 2018 Research & Development Day on Tuesday, April 10, 2018, from 8:30 a.m. to 11:30 a.m. EDT ...
"We have a big year ahead of us."
THE WOODLANDS, Texas, March 29, 2018-- Lexicon Pharmaceuticals, Inc., today announced that the European Medicines Agency has accepted the Marketing Authorization Application filed by Lexicon’ s collaborator, ...
Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: ...
Q4 2017 Lexicon Pharmaceuticals Inc Earnings Call
New Drug Application Submitted to U.S. Marketing Authorization Application Submitted to European Medicines Agency. THE WOODLANDS, Texas, March 26, 2018-- Lexicon Pharmaceuticals, Inc., today announced ...
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
THE WOODLANDS, Texas, Feb. 28, 2018-- Lexicon Pharmaceuticals, Inc., announced today that data from a poster highlighting XERMELO ® will be presented at the upcoming 15 th Annual European Neuroendocrine ...
THE WOODLANDS, Texas, Feb. 27, 2018-- Lexicon Pharmaceuticals, Inc. today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, ...
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
The The Woodlands, Texas-based company said it had a loss of 27 cents per share. Losses, adjusted for pretax gains, came to 31 cents per share. The results exceeded Wall Street expectations. The average ...
Net Sales Since March 2017 Launch Reach $15.1 Million. Regulatory Filings for Sotagliflozin in Patients with Type 1 Diabetes Expected in First Quarter of 2018. THE WOODLANDS, Texas, Feb. 22, 2018-- Lexicon ...
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 8:00 ...
THE WOODLANDS, Texas, Feb. 16, 2018-- Lexicon Pharmaceuticals, Inc., will release its fourth quarter and full-year 2017 financial results on Thursday, February 22, 2018 before market opens. Management ...
The stock was downgraded by a prominent analyst.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
NEW YORK, Feb. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mettler-Toledo ...
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
Analysts think these three diabetes stocks could soar more than 50% this year. But are they right?
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX